#Israel #Jerusalem #Liquid Biopsy #Lightspeed #Senseera

Senseera Secures $7.1 Million Seed Round for Revolutionary Liquid Biopsy Technology

Senseera, an innovative company specializing in liquid biopsy technology, has officially announced the successful closure of a seed funding round totaling $7.1 million. This funding was predominantly led by the esteemed Lightspeed Venture Partners, with contributions from I-Next Capital and the Lowy Medical Research Institute. The investment will significantly bolster Senseera's groundbreaking GEM BIOMARKERS™ platform, which utilizes cutting-edge cfChIP-seq technology. This platform enables the decoding of cell-specific gene expression and cell states through a non-invasive blood draw. The implications of this technology are profound, offering biopsy-level insights with much greater convenience and less patient risk.

The technology developed by Senseera is rooted in years of rigorous research spearheaded by Professor Nir Friedman and boasts validation from prestigious scientific journals like Nature Biotechnology. To date, the platform has been reinforced by data gathered from over 20,000 human samples, providing a solid foundation that drives forward advancements in drug development and precision medicine, particularly in the fields of oncology, immunology, metabolic diseases, and the management of liver diseases.

Globally, liver diseases are a stark health concern, currently affecting nearly 25% of adults. Traditional diagnostic methods frequently involve risky invasive biopsies or non-specific tests, resulting in delays in diagnosis and subpar patient care. Senseera aims to provide an innovative alternative. Its technology promises the early detection and better management of prevalent liver conditions such as MASLD/MASH, hepatocellular carcinoma (HCC), and issues surrounding liver transplant rejection. With this new funding, Senseera is set to expedite the market introduction of its cutting-edge transplant rejection test, push forward clinical trials, and strengthen collaborations with prominent biopharmaceutical companies.

Adding to its unique offerings, Senseera's platform is also geared towards accelerating drug development across cancer and immune disorders. By facilitating simultaneous monitoring of both solid tissue and immune cell states, Senseera's technology enables a deeper understanding of the interactions within the tissue-tumor immune environment. This is pivotal for researchers and clinicians in crafting personalized treatment options.

Dr. Ronen Sadeh, the CEO of Senseera, remarked, "This funding marks a major milestone in our journey to revolutionize diagnostics not just for liver diseases, but to enhance the entire landscape of disease management and drug development. With the backing from Lightspeed and our investors, we will drive forward clinical trials, solidify partnerships with global pharma leaders, and expand our product pipeline to significantly improve patient outcomes."

Overview of Senseera

Senseera stands at the forefront of a new wave in liquid biopsy technology, focusing on chromatin epigenomics that promises to provide deeper insights into various disease states. Their GEM BIOMARKERS™ platform is designed to offer non-invasive detection and monitoring capabilities, pushing the boundaries of personalized medicine through state-of-the-art scientific methodologies and robust molecular analyses. As Senseera continues its growth trajectory, the medical community eagerly anticipates its potential to transform diagnostics and personalized treatment paradigms across a multitude of health challenges.